secwatch.observer — SEC 8-K summary
======================================

Issuer:     Nkarta, Inc. (NKTX)
CIK:        0001787400
Form:       8-K
Filed at:   2021-10-07T23:59:59+00:00
Accession:  0001564590-21-050412
Event type: other_material
Sentiment:  neutral
Materiality: 0.55
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Nkarta doses first patients in NKX019 Ph1; NKX101 initial data guided to 1H 2022
--------------------------------------------------------------------------------

- First patients dosed in Phase 1 trial of NKX019 for CD19+ B-cell malignancies (NHL, CLL, B-ALL).
- Initial data from NKX019 trial expected in 2022.
- Initial data from NKX101 Phase 1 in AML/MDS now expected in first half of 2022 (previously anticipated earlier).
- NKX101 cadence affected by haplomatched donor cell use, staggered enrollment, and COVID-19 disruptions.
- Protocol amended to allow off-the-shelf or haplomatched cells and to shorten patient stagger.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1787400/000156459021050412/0001564590-21-050412-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1787400/000156459021050412/nktx-8k_20211007.htm
  HTML page:      https://secwatch.observer/filing/0001564590-21-050412

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer